Navigation Links
Isis Pharmaceuticals Adds Two New Drugs to Development Pipeline
Date:1/6/2011

CARLSBAD, Calif., Jan. 6, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.  

ISIS-FGFR4Rx is designed to treat obesity by increasing metabolism, particularly by increasing lipid and fat burning.  ISIS-FGFR4Rx specifically blocks the production of fibroblast growth factor receptor 4 (FGFR4) in the liver and fat tissue. In addition, ISIS-FGFR4Rx should not reduce FGFR4 expression in the central nervous system (CNS) or heart, thereby avoiding the CNS and cardiovascular side effects associated with many obesity drugs in development.  In preclinical studies, inhibition of FGFR4 lowered body weight and enhanced weight loss when administered as a single agent, in combination with a caloric-restricted diet and in combination with an appetite-suppressing drug and a caloric-restricted diet.  The reduction in body weight was accompanied by an improvement in insulin sensitivity. ISIS-FGFR4Rx was safe and well tolerated in multiple species.  ISIS-FGFR4Rx is the first drug in Isis' metabolic franchise to treat obesity.  

"Obesity has become an epidemic.  It is a condition that increases the risk of diabetes, heart disease, stroke, arthritis and some cancers, and an area where most centrally acting drugs have failed due to side-effects.  Consequently, our peripherally acting drugs such as ISIS-FGFR4Rx could have significant therapeutic benefit without the associated central nervous system toxicities that plague many other anti-obesity drugs.  Our ability to selectively target FGFR4 in only the tissues where FGFR4 plays an important role in modulating body weight, makes it an ideal target for our antisense technology," said Sanjay Bhanot, M.D., Ph.D., Vice President, Metabolic Disorders and Head of Translational Medicine
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Onyx Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
3. Pier Pharmaceuticals Names Peter Letendre as Chief Executive Officer, President and Director
4. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
5. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
6. Access Pharmaceuticals Raises $6.0 Million In Registered Direct Offering
7. University of Utah and Navigen Pharmaceuticals Announce a New Government Contract to Advance Slit2N for the Treatment of Hemorrhagic Fever and Anthrax Exposure
8. Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study
9. AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock
10. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
11. Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)...   Decision Resources Group finds that ... are its oral administration, alternative mechanism of action, ... rheumatologists. Otezla was the first oral therapy specifically ... psoriatic arthritis in the United States ... conventional oral treatments including disease-modifying antirheumatic drugs (DMARDs), ...
(Date:7/1/2015)... July 1, 2015   Neuraltus Pharmaceuticals, Inc. ... of groundbreaking drugs to treat neurodegenerative diseases such ... Robert G. Miller , M.D., Director of the ... California Pacific Medical Center in San Francisco, has been ... $1.5 million to help fund a Phase 2 ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan ... lower the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s Startup ... prizes of US$15,000 and a period of expert mentorship from a senior industry figure ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... pathogen transmission. CTI’ new Medical Joysticks have an impermeable molecular barrier protection ... an operator control device that will increase healthcare worker safety and reduce financial ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
... PCR system, developed for,highfidelity PCR , , Kirk ... Daniel McMullan,* Barbara McGowan * Holly Hogrefe ,Stratagene Cloning ... the TaqPlus Precision PCR system,* to an expanding line ... a novel mixture of Taq2000 and Pfu DNA polymerases ...
... tools for neuroscience researchers , , Robert ... Browning, Mary Ellen Simcox ,Stratagene Cloning Systems, Inc. ... sets for the rat and human,NMDA receptor. In ... reverse,transcriptase-mediated polymerase chain reaction (RT-PCR) assays to show,expression ...
... ,Over 40% of Stratagenes GeneConnection cDNA gene clusters are ... full-length clones , Jason Goncalves Jean-Michel Lelias ... clone collection YY ,goes beyond normal ... tissues and has identified thousands of cDNAs that are ...
Cached Biology Technology:High-Fidelity PCR with a Novel Polymerase Mixture 2High-Fidelity PCR with a Novel Polymerase Mixture 3High-Fidelity PCR with a Novel Polymerase Mixture 4High-Fidelity PCR with a Novel Polymerase Mixture 5High-Fidelity PCR with a Novel Polymerase Mixture 6High-Fidelity PCR with a Novel Polymerase Mixture 7High-Fidelity PCR with a Novel Polymerase Mixture 8High-Fidelity PCR with a Novel Polymerase Mixture 9High-Fidelity PCR with a Novel Polymerase Mixture 10High-Fidelity PCR with a Novel Polymerase Mixture 11Gene-Specific Primers for NMDA Receptor Subunits 2Gene-Specific Primers for NMDA Receptor Subunits 3Gene-Specific Primers for NMDA Receptor Subunits 4The GeneZoo or the GeneJungle? 2The GeneZoo or the GeneJungle? 3The GeneZoo or the GeneJungle? 4The GeneZoo or the GeneJungle? 5The GeneZoo or the GeneJungle? 6The GeneZoo or the GeneJungle? 7The GeneZoo or the GeneJungle? 8The GeneZoo or the GeneJungle? 9The GeneZoo or the GeneJungle? 10
(Date:6/24/2015)... , June 24, 2015 The biologics safety ... major drivers for the market include growth of the ... new drug launches. Over the years, the number of ... 2001 and 2010, the FDA approved 225 drug applications ... WIPO, Europe accounted for 3,822 ...
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
(Date:6/18/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... market announces that its Wocket® smart wallet will be the ... scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive one ... Inc.,s CEO Gino Pereira will be discussing its ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... University scientists have unveiled a revolutionary new technology that ... The new "solar steam" method from Rice,s Laboratory for ... steam from icy cold water. Details of the ... ACS Nano . The technology has an overall energy ...
... 2012 (Toronto) - The Centre for Addiction and ... psychiatrist Dr. Aristotle Voineskos, Koerner New Scientist and head ... the Campbell Family Mental Health Research Institute, has been ... Prize for university research in Ontario. The Polanyi ...
... of light to a chunk of gray matter smaller than ... and engineers at the Massachusetts Institute of Technology (MIT) in ... of light to a 3-D section of living brain tissue. ... but promising technique that uses gene therapy to turn individual ...
Cached Biology News:Rice unveils super-efficient solar-energy technology 2Rice unveils super-efficient solar-energy technology 3CAMH scientist wins Polanyi Prize 2A 3-D light switch for the brain 2A 3-D light switch for the brain 3A 3-D light switch for the brain 4
... Caliper is proud to work in collaboration ... Certified 25mm syringe filters in a variety ... are licensed for use on the Caliper ... Specifications and Pricing for our Automation Certified ...
The Microseal 384 plate positioner ensures precise positioning of Microseal 384-well plates in the x-, y-, and z-dimensions, for accurate automated liquid handling....
... Thermo-Sealer is a manual heat sealer ideal for ... portable instrument can seal a wide range of ... carriers. The heating element of the sealer is ... or peelable seals when used in conjunction with ...
...
Biology Products: